No Data
No Data
Why Champions Oncology Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing
Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients
Express News | Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in Lvad Patients
Express News | Cadrenal Therapeutics Highlights Manuscript In The Journal of Cardiac Failure Evaluating Relationship Between TTR Management Quality And LVAD Patient Clinical Outcomes
Published Findings Highlight Tecarfarin's Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD Patients
No Data
No Data